MAY 202419TECH OUTLOOKoperational paradigms, focusing on therapeutic interventions like engineered proteins, peptides, oligonucleotides, gene regulation, gene editing, and RNA therapeutics. Recent advancements in targeted protein degradation have gained interest. A key initiative involves integrating molecular and cell sciences, molecular pathology, proteomics, and proteogenomic capabilities to orchestrate pharmacological models in five therapeutic domains. This initiative is crucial during the discovery phase, providing insights into the effects of therapies on cellular, animal, and human models.Andrew: Like Scott mentioned, the goal has been to assemble critical pieces of drug discovery to move projects forward. This involves listening to clients, understanding their pain points, and assembling the appropriate pieces. The appropriate pieces include disease pharmacology and drug metabolism disciplines, coupled with our scientific expertise. The key part of our innovation is our people and experience, which we demonstrate and provide access to our customers to drive their projects forward. This approach ensures that our clients have access to the knowledge and expertise needed to drive their projects forward.Is there any piece of advice that you would like to give to an aspiring professional or a peer that might help them navigate these changes? Scott: I would suggest to focus on the importance of interdisciplinary approach in modern therapeutic intervention for up-and-coming scientists and investigators in the pharma, biopharma, biotech, and CRO industries. Reassembling the right components of the orchestra of science to tackle therapeutic modalities questions, rather than adopting the traditional drug discovery approach is vital. The emphasis should be placed on tailoring solutions for each project, ensuring the alignment of the appropriate drug with the specific needs of the individual patient at the correct juncture. In addition, it is important to have the right model, tools, and analytical framework for each project, along with the involvement of pertinent scientific experts in the respective therapeutic areas. Our objective at Inotive is to grant clients access to a fully assembled and operational drug discovery unit, offering a comprehensive and innovative approach to the entire process. Andrew: Adding to what Scott said, having a good understanding of the various components of drug discovery and being creative in thinking is imperative. Additionally, moving away from the traditional approach, mentioned Scott has its pros and cons but emphasizes the need to understand the various therapeutic areas, stages of drug development, and different modalities with new drugs proves crucial. Being passionate about studying these subjects, advancing them to market or in terms of further development is pivotal for achieving success in the pharmaceutical industry. We at Inotiv, has established a dedicated business unit for drug discovery and translational sciences, aiming to address research questions and tackle challenges in therapeutic developmentAndrew Brown
< Page 9 | Page 11 >